Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the oesophagus whose incidence is on the rise. Despite maximal use of guideline-based therapies including food elimination diets and steroids, many patients remain symptomatic. This review serves to summarize safety and efficacy of monoclonal antibodies in treatment of EoE. There has been an increasing number of biologics under consideration for EoE and several that have undergone clinical trials. mAbs that target specific effectors involved in the disease may offer additional clinical and histologic benefit. In addition, they offer a more benign adverse effect profile than traditional therapies. Biologics for treatment of EoE may result in symptom and histologic improvement and has the potential to treat disease with minimal side effects. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Citation

Simin Zhang, Amal H Assa'ad. Biologics in eosinophilic esophagitis. Current opinion in allergy and clinical immunology. 2021 Jun 01;21(3):292-296


PMID: 33769314

View Full Text